TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 11199955
Drug: Quetiapine administered
Approvals — FDA: no, EMA: no, PMDA: no
Description: Quetiapine administered concomitantly with phenytoin
Study: 22212516
Drug: IABP therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: IABP therapy
Study: 31020797
Drug: Control group
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control group (no IABP therapy)
Study: 21353104
Drug: Atorvastatin 5
Normalized name: amlodipine-atorvastatin 5 mg-80 mg oral tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Atorvastatin 5 mg/d
Study: 19791551
Drug: Mexicor (0.3
Approvals — FDA: no, EMA: no, PMDA: no
Description: Mexicor (0.3 g per day for 3 weeks)
Study: 19791551
Drug: Conventional therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Conventional therapy (Aspirin Cardio, Trental, Prestarium, Arifon)
Study: 10397685
Drug: 5.1 g/d
Approvals — FDA: no, EMA: no, PMDA: no
Description: 5.1 g/d n‐3 FA for 6 months
Study: 6704277
Drug: 1.5 ml
Normalized name: Humulin 70/30 1.5 ML Pen
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1.5 ml glucose-free 0.5% bupivacaine
Study: 6704277
Drug: 2 ml
Normalized name: ethanol 2 ML/ML
Approvals — FDA: no, EMA: no, PMDA: no
Description: 2 ml glucose-free 0.5% bupivacaine
Study: 6704277
Drug: 3 ml
Normalized name: WATER,INHL 3 ML
Approvals — FDA: no, EMA: no, PMDA: no
Description: 3 ml glucose-free 0.5% bupivacaine
Study: 6704277
Drug: 4 ml
Normalized name: ethanol 1.4 ML/ML
Approvals — FDA: no, EMA: no, PMDA: no
Description: 4 ml glucose-free 0.5% bupivacaine
Study: 29031513
Drug: Specific cues
Normalized name: Pacific halibut
DrugBank: Pacific halibut (DB10616)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Specific cues about upcoming hazards (e.g., 'crosswalk ahead')
Study: 27543530
Drug: Saline group
Approvals — FDA: no, EMA: no, PMDA: no
Description: Saline group (received ultrasound‐guided saline injection in the ilioinguinal and iliohypogastric nerve region before surgery and ropivacaine after surgery)
Study: 27543530
Drug: Block group
Normalized name: Ivy Block
Approvals — FDA: no, EMA: no, PMDA: no
Description: Block group (received injections in the opposite order: ropivacaine before surgery and saline after surgery)
Study: 22105837
Drug: Antimicrobial photodynamic
Normalized name: GAUZE,ANTIMICROBIAL
Approvals — FDA: no, EMA: no, PMDA: no
Description: Antimicrobial photodynamic therapy (PDT)
Study: 22105837
Drug: Diode soft
Approvals — FDA: no, EMA: no, PMDA: no
Description: Diode soft laser therapy (DSL)
Study: 18387426
Drug: Probiotic combination
Normalized name: PROBIOTIC COMBINATION CAP/TAB
Approvals — FDA: no, EMA: no, PMDA: no
Description: Probiotic combination (1 x 10(10) cfu once daily) for four weeks
Study: 16354821
Drug: Azithromycin 1,000
Approvals — FDA: no, EMA: no, PMDA: no
Description: Azithromycin 1,000 mg q.d. x 3
Study: 16354821
Drug: Chloroquine 600
Normalized name: Chloroquine
DrugBank: Chloroquine (DB00608)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Chloroquine 600 mg q.d. x 2 then 300 mg on Day 3 followed by primaquine on Days 7 through 20
Study: 12757214
Drug: Combined albendazole
Normalized name: Albendazole
DrugBank: Albendazole (DB00518)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Combined albendazole 400 mg and praziquantel 20 mg/kg
Study: 12757214
Drug: Albendazole 800
Normalized name: Albendazole
DrugBank: Albendazole (DB00518)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Albendazole 800 mg as a single dose
Study: 12757214
Drug: Tinidazole 50
Normalized name: tinidazole 500 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tinidazole 50 mg/kg as a single dose
Study: 11212974
Drug: Amlodipine (5-10
Approvals — FDA: no, EMA: no, PMDA: no
Description: Amlodipine (5-10 mg)
Study: 7018182
Drug: Peroral estrogen
Normalized name: estrogens
Approvals — FDA: no, EMA: no, PMDA: no
Description: Peroral estrogen (estradiol valerate), 4 mg daily
Study: 26803746
Drug: Celecoxib administration
Normalized name: Celecoxib
DrugBank: Celecoxib (DB00482)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Celecoxib administration immediately after surgery
Study: 26803746
Drug: No celecoxib
Normalized name: Celecoxib
DrugBank: Celecoxib (DB00482)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: No celecoxib administration (control)
Study: 24981241
Drug: Local anesthesia
Normalized name: Esters of benzoic acid for local anesthesia
Approvals — FDA: no, EMA: no, PMDA: no
Description: Local anesthesia with intravenous sedation
Study: 22502753
Drug: Intracoronary BMNCs
Normalized name: HELIUM 992 mL in 1 L INTRACORONARY GAS
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intracoronary BMNCs injection (n=17, BMNCs group)
Study: 22502753
Drug: Standard therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard therapy (n=10, Control group)
Study: 17381977
Drug: Fluid Restriction
Normalized name: amniotic fluid (bovine)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fluid Restriction (FR): 193 (sem 19) ml water/d
Study: 17381977
Drug: Fluid and
Normalized name: amniotic fluid (bovine)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fluid and Energy Restriction (F+ER): Combination of FR and ER
Study: 17381977
Drug: Control: Estimated
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control: Estimated energy (12,154 (sem 230) kJ/d) and water (3912 (sem 140) ml/d) requirements
Study: 11519769
Drug: Bupropion SR
Normalized name: Bupropion Hydrochloride 100 MG Oral Tablet, Extended Release, 12 HR [BUPROPION SR]
DrugBank: Bupropion (DB01156)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Bupropion SR 150 to 400 mg/d
Study: 11519769
Drug: Fluoxetine 20
Normalized name: fluoxetine 20 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fluoxetine 20 to 60 mg/d
Study: 8192170
Drug: Fluvastatin (40
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fluvastatin (40 mg/d) + Bezafibrate (400 mg/d)
Study: 8192170
Drug: Fluvastatin (40
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fluvastatin (40 mg/d) + Cholestyramine
Study: 8192170
Drug: Fluvastatin monotherapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fluvastatin monotherapy (40 mg/d)
Study: 3130892
Drug: Sodium valproate
Normalized name: sodium valproate
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sodium valproate (VPA; 500 mg thrice daily for 7 days)
Study: 30845330
Drug: Vi-typhoid conjugate
Normalized name: typhoid Vi polysaccharide vaccine, S typhi Ty2 strain
DrugBank: Typhoid Vi polysaccharide vaccine (DB10803)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Vi-typhoid conjugate vaccine (Vi-TCV) co-administered with yellow fever vaccine (YFV) at 9 months and meningococcal A conjugate vaccine (MCV-A) at 15 months.
Study: 24867230
Drug: Clot-SRV (50
Approvals — FDA: no, EMA: no, PMDA: no
Description: Clot-SRV (50 mg of clotrimazole once a day)
Study: 24867230
Drug: Clotrimazole troches
Normalized name: clotrimazole
DrugBank: Clotrimazole (DB00257)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Clotrimazole troches (5 troches of 10 mg clotrimazole/day)
Study: 19738036
Drug: Prednisone (0.8
Approvals — FDA: no, EMA: no, PMDA: no
Description: Prednisone (0.8 mg x kg(‐1) x day(‐1))
Study: 17873675
Drug: Escitalopram 10
Normalized name: escitalopram 10 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Escitalopram 10 mg for 12 weeks
Study: 17873675
Drug: Escitalopram 10
Normalized name: escitalopram 10 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Escitalopram 10 mg at 6-month follow-up
Study: 17873675
Drug: Escitalopram 10
Normalized name: escitalopram 10 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Escitalopram 10 mg at 12 weeks
Study: 15738918
Drug: Reconstruction of
Normalized name: OIL OF CAMPHOR
Approvals — FDA: no, EMA: no, PMDA: no
Description: Reconstruction of three-dimensional dose distributions from two-dimensional treatment plan information
Study: 9176441
Drug: Angiotensin II
Normalized name: Angiotensin II
DrugBank: Angiotensin II (DB11842)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Angiotensin II immunoreactivity in ascites from pregnant OHSS (1,669 ± 418 pg/mL)
Study: 31774002
Drug: Transcutaneous electrical
Normalized name: Transcutaneous Electrical Nerve Stimulators (TENS Units) MISCELL EACH
Approvals — FDA: no, EMA: no, PMDA: no
Description: Transcutaneous electrical nerve stimulation (TENS) combined with oral lactulose solution
Study: 31774002
Drug: Oral lactulose
Normalized name: Lactulose
DrugBank: Lactulose (DB00581)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Oral lactulose solution
Study: 27495097
Drug: Home-based exercise
Approvals — FDA: no, EMA: no, PMDA: no
Description: Home-based exercise training program (cycling 3 times weekly for 35 minutes for 24 weeks)
Study: 22240839
Drug: Gabapentin (200
Approvals — FDA: no, EMA: no, PMDA: no
Description: Gabapentin (200 mg) alone
Study: 22240839
Drug: Gabapentin (200
Approvals — FDA: no, EMA: no, PMDA: no
Description: Gabapentin (200 mg) + 1 g magnesium oxide (MgO)
Study: 22240839
Drug: Gabapentin (200
Approvals — FDA: no, EMA: no, PMDA: no
Description: Gabapentin (200 mg) + 20 mg omeprazole
Study: 20017166
Drug: Conventional-dose radiotherapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Conventional-dose radiotherapy (<74 Gy) with hormonal therapy
Study: 20017166
Drug: Escalated-dose radiotherapy
Normalized name: peanut allergenic extract
Approvals — FDA: no, EMA: no, PMDA: no
Description: Escalated-dose radiotherapy (≥74 Gy) with hormonal therapy
Study: 20017166
Drug: Moderately escalated
Approvals — FDA: no, EMA: no, PMDA: no
Description: Moderately escalated dose (74 Gy) with hormonal therapy
Study: 20017166
Drug: High escalated
Normalized name: high-density polyethylene
Approvals — FDA: no, EMA: no, PMDA: no
Description: High escalated dose (≥78 Gy) with hormonal therapy
Study: 18664024
Drug: Acute normovolaemic
Approvals — FDA: no, EMA: no, PMDA: no
Description: Acute normovolaemic haemodilution (ANH) with crystalloids (saline solution)
Study: 8707264
Drug: Tapering interferon
Normalized name: Interferon Gamma
DrugBank: Interferon Gamma (DB15753)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tapering interferon (IFN) dose (3 mu, 2 mU, 1 mU, and 0.5 mU three times a week, then 0.5 mU twice weekly and once weekly)
Study: 8707264
Drug: Stopping interferon
Approvals — FDA: no, EMA: no, PMDA: no
Description: Stopping interferon (IFN) treatment
Study: 8707264
Drug: Tapering interferon
Normalized name: Interferon Gamma
DrugBank: Interferon Gamma (DB15753)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tapering interferon (IFN) dose
Study: 8452178
Drug: fleroxacin 400
Normalized name: fleroxacin 400 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: fleroxacin 400 mg for 1 day
Study: 8452178
Drug: fleroxacin 400
Normalized name: fleroxacin 400 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: fleroxacin 400 mg daily for 2 days
Study: 3006449
Drug: Captopril 150
Normalized name: Captopril
DrugBank: Captopril (DB01197)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Captopril 150 mg
Study: 19592202
Drug: Computer-assisted insulin
Normalized name: INSULIN
DrugBank: Insulin beef (DB09456)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Computer-assisted insulin protocol (CAIP)
Study: 15118193
Drug: Reconstituted fruit
Approvals — FDA: no, EMA: no, PMDA: no
Description: Reconstituted fruit juice (FJ, 10.4% total carbohydrate, 489 mosmol/L, pH= 3.2)
Study: 15118193
Drug: Flavored water
Normalized name: FLAVOR
Approvals — FDA: no, EMA: no, PMDA: no
Description: Flavored water (FW, no carbohydrate, osmolality = 48 mosmol/L, pH = 3.3)
Study: 15118193
Drug: Sports drink
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sports drink (SD, 6% total carbohydrate, 295 mosmol/L, pH = 3.3)
Study: 11172512
Drug: Intrathecal hyperbaric
Normalized name: beractant
DrugBank: Beractant (DB06761)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Intrathecal hyperbaric bupivacaine 3.75 mg with fentanyl 25 microg
Study: 11172512
Drug: Hyperbaric lidocaine
Normalized name: Lidocaine
DrugBank: Lidocaine (DB00281)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Hyperbaric lidocaine 30 mg with fentanyl 25 microg
Study: 3578568
Drug: Paraprofessional drug
Normalized name: Clearskin Professional Daily Correcting
DrugBank: Salicylic acid (DB00936)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Paraprofessional drug counseling
Study: 30562785
Drug: Intranasal placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intranasal placebo (0.9% saline) 0.02 mL/kg
Study: 22414688
Drug: Beetroot juice
Normalized name: tamarind juice
Approvals — FDA: no, EMA: no, PMDA: no
Description: Beetroot juice (BJ) 0, 100, 250, and 500 g
Study: 22414688
Drug: Red beetroot-enriched
Approvals — FDA: no, EMA: no, PMDA: no
Description: Red beetroot-enriched bread (100 g)
Study: 22414688
Drug: Control bread
Normalized name: Eazi-Breed CIDR
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control bread (0 g beetroot)
Study: 21079163
Drug: Buffered preservative‐free
Approvals — FDA: no, EMA: no, PMDA: no
Description: Buffered preservative‐free acidified solution in saline nasal spray
Study: 21079163
Drug: Benzalkonium chloride‐containing
Approvals — FDA: no, EMA: no, PMDA: no
Description: Benzalkonium chloride‐containing saline nasal spray
Study: 21079163
Drug: Both nasal
Normalized name: Bothrops atrox venom
Approvals — FDA: no, EMA: no, PMDA: no
Description: Both nasal spray solutions
Study: 12847284
Drug: Live recombinant
Approvals — FDA: no, EMA: no, PMDA: no
Description: Live recombinant canarypox ALVAC-HIV vaccine with or without rgp120/SF-2
Study: 10439770
Drug: Granisetron 2.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Granisetron 2.5 mg
Study: 8537681
Drug: Two doses
Approvals — FDA: no, EMA: no, PMDA: no
Description: Two doses of 10(7) TCID50 of live, attenuated cold‐adapted influenza A/Kawasaki/86 (H1N1) reassortant virus vaccine
Study: 8537681
Drug: Two doses
Approvals — FDA: no, EMA: no, PMDA: no
Description: Two doses of 10(7) TCID50 of ca influenza virus
Study: 1925862
Drug: Surgical treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Surgical treatment followed by radiation therapy (102 patients), total dose of 45 to 55 Grays delivered to specific areas.
Study: 1925862
Drug: Isolated surgical
Normalized name: ISOLATE
Approvals — FDA: no, EMA: no, PMDA: no
Description: Isolated surgical treatment (119 patients).
Study: 1925862
Drug: Surgical treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Surgical treatment followed by radiation therapy (102 patients).
Study: 6958488
Drug: Budesonide 400
Normalized name: Budesonide 400 microgram/actuation powder for inhalation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Budesonide 400 micrograms daily for 4 months
Study: 22252927
Drug: Acupuncture-like transcutaneous
Normalized name: insulin-like growth factor 2
DrugBank: Insulin-like growth factor II (DB14472)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Acupuncture-like transcutaneous electrical nerve stimulation (ALTENS) - 24 sessions over 12 weeks, twice weekly.
Study: 19463151
Drug: HX575 (100
Approvals — FDA: no, EMA: no, PMDA: no
Description: HX575 (100 IU/kg body weight, intravenous, three-times-weekly for four weeks)
Study: 19463151
Drug: Comparator epoetin
Normalized name: Epoetin
DrugBank: Erythropoietin (DB00016)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Comparator epoetin alfa (100 IU/kg body weight, intravenous, three-times-weekly for four weeks)
Study: 9795453
Drug: 90-ml oral
Normalized name: ethanol
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 90-ml oral sodium phosphate (NaP)
Study: 9795453
Drug: 45-ml oral
Normalized name: PROSOURCE TF LIQUID,ORAL,45ML
Approvals — FDA: no, EMA: no, PMDA: no
Description: 45-ml oral sodium phosphate (NaP)
Study: 7709404
Drug: Picotamide (300
Approvals — FDA: no, EMA: no, PMDA: no
Description: Picotamide (300 mg TID)
Study: 2796621
Drug: Aminophylline 2
Normalized name: aminophylline 200 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Aminophylline 2 mg/kg iv
Study: 2796621
Drug: Physostigmine 1
Normalized name: PHYSostigmine 1 mg/mL injectable solution
Approvals — FDA: no, EMA: no, PMDA: no
Description: Physostigmine 1 mg iv and naloxone 0.4 mg im
Study: 66567
Drug: Metiamide (nocturnal
Approvals — FDA: no, EMA: no, PMDA: no
Description: Metiamide (nocturnal administration)
Study: 66567
Drug: Metiamide (continued
Approvals — FDA: no, EMA: no, PMDA: no
Description: Metiamide (continued administration for 1 year)
Study: 66567
Drug: Metiamide (cessation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Metiamide (cessation of treatment)
Study: 31475495
Drug: Medication (Climen,
Approvals — FDA: no, EMA: no, PMDA: no
Description: Medication (Climen, 1 tablet/d for 21 days)
Study: 31475495
Drug: Acupuncture (manual
Approvals — FDA: no, EMA: no, PMDA: no
Description: Acupuncture (manual stimulation of specific points from day 8 to 15 of menstruation, once daily for 3 cycles)
Study: 31475495
Drug: Combined treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combined treatment (acupuncture + medication)
Study: 31475495
Drug: Combined treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combined treatment vs Acupuncture
Study: 31475495
Drug: Combined treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combined treatment vs Medication
Study: 31475495
Drug: Acupuncture vs
Normalized name: VS-4718
DrugBank: VS-4718 (DB15273)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Acupuncture vs Medication
Study: 21672493
Drug: ziprasidone, 20‐80
Approvals — FDA: no, EMA: no, PMDA: no
Description: ziprasidone, 20‐80 mg twice a day
Study: 21672493
Drug: placebo twice
Approvals — FDA: no, EMA: no, PMDA: no
Description: placebo twice a day
Study: 18636953
Drug: Parenteral MenB
Approvals — FDA: no, EMA: no, PMDA: no
Description: Parenteral MenB outer membrane vesicle vaccine
Study: 1419223
Drug: Astemizole 5
Normalized name: astemizole 5 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Astemizole 5 mg daily for 2 weeks followed by increasing doses (5, 10, 20, 40 mg per day)
Study: 1419223
Drug: Astemizole 10
Normalized name: astemizole 10 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Astemizole 10 mg daily for 12 weeks
Study: 30643081
Drug: Proton Pump
Normalized name: Proton pump inhibitor
Approvals — FDA: no, EMA: no, PMDA: no
Description: Proton Pump Inhibitor (PPI) - esomeprazole
Study: 30643081
Drug: Histamine H2
Normalized name: Histamine H2 receptor
Approvals — FDA: no, EMA: no, PMDA: no
Description: Histamine H2 receptor antagonist (H2 blocker) - famotidine
Study: 20077670
Drug: Domestic split
Normalized name: domestic cow dander extract
Approvals — FDA: no, EMA: no, PMDA: no
Description: Domestic split influenza virus vaccine
Study: 20077670
Drug: Imported split
Normalized name: black imported fire ant allergenic extract
DrugBank: Solenopsis richteri (DB11026)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Imported split influenza virus vaccine
Study: 17341027
Drug: 250 mg
Normalized name: rutin 250 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 250 mg flucloxacillin capsules
Study: 7761016
Drug: Total Intravenous
Normalized name: Colgate Total Mouthwash
Approvals — FDA: no, EMA: no, PMDA: no
Description: Total Intravenous Anaesthesia (TIVA): propofol + fentanyl + pancuronio bromide
Study: 3260794
Drug: Magnesium chloride
Normalized name: Magnesium Chloride
DrugBank: Magnesium chloride (DB09407)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Magnesium chloride 16 mmol in 10 ml of water
Study: 3260794
Drug: 10 ml
Normalized name: Vial Empty 10 mL
Approvals — FDA: no, EMA: no, PMDA: no
Description: 10 ml of water alone (control group)
Study: 31928690
Drug: Alpelisib in
Normalized name: Product containing alpelisib in oral dose form (medicinal product form)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Alpelisib in combination with fulvestrant
Study: 29878340
Drug: Erenumab 140
Normalized name: Erenumab 140 mg/mL solution for injection
Approvals — FDA: no, EMA: no, PMDA: no
Description: Erenumab 140 mg IV infusion
Study: 28157100
Drug: Donepezil (5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Donepezil (5 mg for 6 weeks and 10 mg for 18 weeks)
Study: 9434648
Drug: Reduced-fat diet
Normalized name: Hard fat
DrugBank: Hard fat (DB11578)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Reduced-fat diet (ad libitum) with dietary assessment and education followed by monthly meetings to reduce fat intake (months 1-6)
Study: 2574958
Drug: Amitriptyline (75
Approvals — FDA: no, EMA: no, PMDA: no
Description: Amitriptyline (75 mg/day) and distigmine (10 mg/day)
Study: 2574958
Drug: Addition of
Normalized name: OIL OF CAMPHOR
Approvals — FDA: no, EMA: no, PMDA: no
Description: Addition of distigmine to preexisting amitriptyline treatment
Study: 1139387
Drug: Atropine 0.4
Normalized name: atropine 0.4 mg oral tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Atropine 0.4 mg
Study: 1139387
Drug: Atropine (intravenous)
Normalized name: Atropine
DrugBank: Atropine (DB00572)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Atropine (intravenous)
Study: 1139387
Drug: Glycopyrrolate (intramuscular)
Normalized name: Glycopyrrolate
DrugBank: Glycopyrronium (DB00986)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Glycopyrrolate (intramuscular)
Study: 23992557
Drug: Colchicine (0.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Colchicine (0.5 mg twice daily for patients >70 kg or 0.5 mg once daily for patients ≤70 kg)
Study: 18679038
Drug: Responder group
Normalized name: Streptococcus viridans group
Approvals — FDA: no, EMA: no, PMDA: no
Description: Responder group (depressive patients responding to treatment)
Study: 18679038
Drug: Unresponsive group
Normalized name: Streptococcus viridans group
Approvals — FDA: no, EMA: no, PMDA: no
Description: Unresponsive group (depressive patients not responding to treatment)
Study: 16544257
Drug: Combination therapies
Normalized name: REGN10933+REGN10987 combination therapy
DrugBank: Anti-SARS-CoV-2 REGN-COV2 (DB15691)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination therapies (specific types not detailed)
Study: 16544257
Drug: Intermittent presumptive
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intermittent presumptive therapy, improved case management, and reduction in transmission intensity
Study: 15230074
Drug: Opioid agonist
Approvals — FDA: no, EMA: no, PMDA: no
Description: Opioid agonist treatment (n = 203)
Study: 15230074
Drug: Medication-free treatment
Normalized name: zinc pyrithione Medicated Shampoo [Head & Shoulders Damage Treatment]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Medication-free treatment (n = 155)
Study: 11473971
Drug: Lofexidine hydrochloride
Normalized name: LOFEXIDINE HYDROCHLORIDE
DrugBank: Lofexidine (DB04948)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Lofexidine hydrochloride (up to 600 mg twice daily over 8 weeks)
Study: 2600210
Drug: TRUE Test
Normalized name: SunMark True Test Strips
Approvals — FDA: no, EMA: no, PMDA: no
Description: TRUE Test patch test system
Study: 30372440
Drug: Cash-based intervention
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cash-based intervention (CBI) - monthly unconditional cash transfer of US$84.00 for 5 months, non-food-items kit distribution, provision of piped water free of charge.
Study: 27560540
Drug: Guanidinoacetic acid
Normalized name: Guanidinoacetic acid
Approvals — FDA: no, EMA: no, PMDA: no
Description: Guanidinoacetic acid (GAA) 3.0 g/day
Study: 20467188
Drug: Pioglitazone 30
Normalized name: pioglitazone 30 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pioglitazone 30 mg/day for 16 weeks